Apparently, in metastatic melanoma cell line A375M, treatment with vemurafenib inhibits BRAF, thereby stopping signal transduction to the ERK protein, and it reactivates this signaling pathway after acquiring resistance to vemurafenib (Figure 5B). This evidence concerns the gene BRAF and metastatic melanoma.